Exploring Second-Line Treatments for PBC

Author(s):

Ryan Haumschild, PharmD, MS, MBA, CPEL ,Sandy Sallam, PharmD, BCACP, CDCES

Panelists discuss how some patients with primary biliary cholangitis (PBC) have an inadequate response to ursodeoxycholic acid and require second-line treatments, with options including obeticholic acid, seladelpar, and elafibranor, which improve bile acid homeostasis and reduce inflammation.

EP: 1.Presentation and Diagnosis of Primary Biliary Cholangitis

EP: 2.Available Treatment Options for PBC

EP: 3.Treatment Goals for Patients With PBC

Now Viewing

EP: 4.Exploring Second-Line Treatments for PBC

Video content above is prompted by the following:

How often do patients require second-line treatments for PBC, and what agents are available for second-line management?
How do the mechanisms of action differ between seladelpar, elafibranor, and obeticholic acid?